These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1876 related articles for article (PubMed ID: 31838007)

  • 1. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
    Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
    Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
    Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
    Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T
    Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
    Desai AV; Robinson GW; Gauvain K; Basu EM; Macy ME; Maese L; Whipple NS; Sabnis AJ; Foster JH; Shusterman S; Yoon J; Weiss BD; Abdelbaki MS; Armstrong AE; Cash T; Pratilas CA; Corradini N; Marshall LV; Farid-Kapadia M; Chohan S; Devlin C; Meneses-Lorente G; Cardenas A; Hutchinson KE; Bergthold G; Caron H; Chow Maneval E; Gajjar A; Fox E
    Neuro Oncol; 2022 Oct; 24(10):1776-1789. PubMed ID: 35395680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving role of entrectinib in treatment of
    Chawla N; Bui NQ; Seetharam M
    Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
    Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E; Scaltriti M; Drilon A
    Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting TRK family proteins in cancer.
    Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
    Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
    Kim EE; Park CK; Kim SK; Phi JH; Paek SH; Choi JY; Kang HJ; Lee JH; Won JK; Yun H; Park SH
    Acta Neuropathol Commun; 2024 Jul; 12(1):118. PubMed ID: 39014476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and treatment patterns of patients with
    Willis C; Au T; Hejazi A; Griswold C; Schabath MB; Thompson J; Malhotra J; Federman N; Ko G; Appukkuttan S; Warnock N; Kong SX; Hocum B; Brixner D; Stenehjem D
    J Manag Care Spec Pharm; 2024 Jul; 30(7):672-683. PubMed ID: 38950155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
    Frampton JE
    Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic
    Dziadziuszko R; Krebs MG; De Braud F; Siena S; Drilon A; Doebele RC; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Farago AF; Lin CC; Karapetis CS; Li YC; Day BM; Chen D; Wilson TR; Barlesi F
    J Clin Oncol; 2021 Apr; 39(11):1253-1263. PubMed ID: 33646820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
    J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Entrectinib for the Treatment of
    Marcus L; Donoghue M; Aungst S; Myers CE; Helms WS; Shen G; Zhao H; Stephens O; Keegan P; Pazdur R
    Clin Cancer Res; 2021 Feb; 27(4):928-932. PubMed ID: 32967940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
    Delaye M; Rodrigues M
    Bull Cancer; 2020 Nov; 107(11):1085-1086. PubMed ID: 33169692
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
    Paz-Ares L; Barlesi F; Siena S; Ahn MJ; Drilon A; Conley A; Rolfo C; Wolf J; Seto T; Doebele R; Kapre A; Chen D; McCallum S; Osborne S; Demetri G
    ESMO Open; 2021 Jun; 6(3):100113. PubMed ID: 33930659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
    Demetri GD; De Braud F; Drilon A; Siena S; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Lin JJ; Goto K; Lee J; Bazhenova L; John T; Fakih M; Chawla SP; Dziadziuszko R; Seto T; Heinzmann S; Pitcher B; Chen D; Wilson TR; Rolfo C
    Clin Cancer Res; 2022 Apr; 28(7):1302-1312. PubMed ID: 35144967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tropomyosin receptor kinase inhibitors in the management of sarcomas.
    Wilding CP; Loong HH; Huang PH; Jones RL
    Curr Opin Oncol; 2020 Jul; 32(4):307-313. PubMed ID: 32541318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 94.